Regulus Therapeutics Inc. (NASDAQ:RGLS)’s share price was down 2.7% during mid-day trading on Tuesday . The company traded as low as $3.49 and last traded at $3.54, with a volume of 248,763 shares. The stock had previously closed at $3.64.

A number of equities analysts have recently issued reports on RGLS shares. Needham & Company LLC restated a “buy” rating on shares of Regulus Therapeutics in a research report on Tuesday, May 3rd. Wells Fargo & Co. assumed coverage on Regulus Therapeutics in a report on Tuesday, May 3rd. They issued a “buy” rating for the company. Cowen and Company reiterated a “buy” rating on shares of Regulus Therapeutics in a report on Monday, May 2nd. BMO Capital Markets reiterated a “buy” rating on shares of Regulus Therapeutics in a report on Monday, May 2nd. Finally, Zacks Investment Research downgraded Regulus Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, May 6th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $10.17.

The company’s 50 day moving average price is $3.48 and its 200 day moving average price is $5.58. The stock’s market capitalization is $179.00 million.

Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by $0.02. Equities analysts expect that Regulus Therapeutics Inc. will post ($1.59) EPS for the current fiscal year.

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.